Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Clinical Trials: Overview01:11

Clinical Trials: Overview

2.8K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.8K
Blind Procedures02:07

Blind Procedures

10.6K
Ideally, the people who observe and record the children’s behavior are unaware of who was assigned to the experimental or control group, in order to control for experimenter bias. Experimenter bias refers to the possibility that a researcher’s expectations might skew the results of the study. Remember, conducting an experiment requires a lot of planning, and the people involved in the research project have a vested interest in supporting their hypotheses. If the observers knew which...
10.6K
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
Hazard Ratio01:12

Hazard Ratio

91
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
91
Blinding01:11

Blinding

2.4K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.4K
Clinical Trials01:16

Clinical Trials

6.6K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
6.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same author

Prognostic Value of Restaging [<sup>18</sup>F]FDG PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [<sup>177</sup>Lu]Lu-PSMA-617 Therapy.

Journal of nuclear medicine : official publication, Society of Nuclear Medicine·2026
Same author

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.

Future oncology (London, England)·2026
Same author

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes.

Future oncology (London, England)·2026
Same author

Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trial.

Journal of pharmacokinetics and pharmacodynamics·2026
Same author

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

The New England journal of medicine·2026
Same journal

Belantamab mafodotin, a BCMA-directed antibody-drug conjugate for multiple myeloma.

Future oncology (London, England)·2026
Same journal

Transportability of tislelizumab trial outcomes from RATIONALE-315, RATIONALE-303, and RATIONALE-312 to the European population in early-stage non-small cell lung cancer (NSCLC), advanced NSCLC and extensive-stage small cell lung cancer (ES-SCLC).

Future oncology (London, England)·2026
Same journal

Plain language summary of the MiroCIP study: how often chemotherapy-induced peripheral neuropathy happens in the first year of oxaliplatin- or taxane-based chemotherapy.

Future oncology (London, England)·2026
Same journal

Study of brentuximab vedotin combination treatment in people with early-stage Hodgkin lymphoma: a plain language summary.

Future oncology (London, England)·2026
Same journal

How enzalutamide affects sex life and how taking a break from treatment affects quality of life: a plain language summary of results from the EMBARK study in people with hormone-sensitive prostate cancer and high-risk biochemical recurrence.

Future oncology (London, England)·2026
Same journal

Physician perspectives on the decision-making process for patients with high-risk early-stage triple-negative breast cancer in a community oncology setting.

Future oncology (London, England)·2026
查看所有相关文章

相关实验视频

Updated: Jun 9, 2025

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.3K

塔拉普罗-3研究设计:一个简单的语言摘要.

Neeraj Agarwal1, Fred Saad2, Arun A Azad3

  • 1Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT, USA.

Future oncology (London, England)
|October 25, 2024
PubMed
概括
此摘要是机器生成的。

在TALAPRO-3研究中,研究了Talazoparib加Enzalutamide用于转移性割敏感前列腺癌. 这项试验将组合治疗与安慰剂加恩扎胺进行比较,以评估DNA修复基因变异患者的生存结果.

更多相关视频

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

9.8K

相关实验视频

Last Updated: Jun 9, 2025

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.3K
A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
00:04

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.6K
A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development
07:02

A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development

Published on: February 11, 2019

9.8K

科学领域:

  • 在瘤学瘤学.
  • 生殖尿道癌症 生殖尿道癌症
  • 临床试验 临床试验

背景情况:

  • 转移性割敏感前列腺癌 (mCSPC) 是已经扩散到身体其他部位的前列腺癌,并且对降低的治疗有反应.
  • 患有mCSPC和特定DNA修复基因变异的患者代表了一个尚未满足治疗需求的人群.
  • 了解新型治疗组合的疗效对于推进前列腺癌治疗至关重要.

研究的目的:

  • 在mCSPC和DNA修复基因变异的患者中,评估talazoparib加酶胺与安慰剂加酶胺的疗效.
  • 为了确定组合疗法是否改善整体存活率和无进展存活率.
  • 评估接受试验治疗的患者的安全性,耐受性和生活质量.

主要方法:

  • 塔拉普罗-3研究是一项随机对照临床试验,涉及27个国家的599名患者.
  • 参与者被分配给接受talazoparib加酶胺或安慰剂加酶胺.
  • 结果包括整体存活率,无病变存活率,安全性概况以及患者报告的疼痛和生活质量.

主要成果:

  • 该研究正在进行中,主要疗效结果正在等待.
  • 在整个试验过程中,将收集和分析临时安全数据.
  • 探索性分析可以研究可预测治疗反应的生物标志物.

结论:

  • 该TALAPRO-3研究将提供有关talazoparib加Enzalutamide对mCSPC的疗效和安全性的关键数据.
  • 这些发现可能会为患有特定遗传变异的患者制定新的护理标准.
  • 结果将为晚期前列腺癌治疗的未来研究方向提供信息.